Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR plus breast cancer: A retrospective multicenter study

被引：0
|
作者：
Yildirim, E. Caliskan [1 ]
Atag, E. [1 ]
Yuzugullu, E. [2 ]
Unal, O. U. [3 ]
Celebi, A. [4 ]
Keser, M. [5 ]
Uzun, M.
Keskinkilic, M. [6 ]
Simsek, E. Tanrikulu [7 ]
Sari, M. [8 ]
Yavuzsen, T. [6 ]
机构：
[1] Dokuz Eylul Univ, Dept Med Oncol, Fac Med, Izmir, Turkiye
[2] Haydarpasa Numune Educ & Res Hosp, Med Oncol, Istanbul, Turkiye
[3] Tepecik Educ & Res Hosp, Med Oncol, Izmir, Turkiye
[4] Marmara Univ Pendik Training & Res State Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Tepecik Training & Res Hosp, Med Oncol Dept, Izmir, Turkiye
[6] Dokuz Eylul Univ, Dept Med Oncol, Sch Med, Izmir, Turkiye
[7] Haydarpasa Numune Educ & Res Hosp, Med Oncol Dept, Istanbul, Turkiye
[8] Marmara Univ Pendik Training & Res State Hosp, Dept Med Oncol, Istanbul, Turkiye
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468P
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [1] Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study
    Wu, Yun
    Mo, Hongnan
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    Ma, Fei
    Xu, Binghe
    THORACIC CANCER, 2024, 15 (12) : 965 - 973
  • [2] Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
    Brian Dong
    Rita Lusen
    Ella Chick
    Lisa Kline
    Oncology and Therapy, 2023, 11 : 411 - 418
  • [3] Therapy of advanced HR +, HER2 Breast Cancer Live progression-free longer with CDK4/6 Inhibitor
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 367 - 367
  • [4] The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
    Yildirim, Eda Caliskan
    Atag, Elif
    Coban, Ezgi
    Unal, Olcun Umit
    Celebi, Abdussamet
    Keser, Murat
    Uzun, Mehmet
    Keskinkilic, Merve
    Simsek, Eda Tanrikulu
    Sari, Murat
    Yavuzsen, Tugba
    BREAST, 2023, 70 : 56 - 62
  • [5] Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2-breast cancer: a multicenter real-world data analysis
    Ralser, Damian J.
    Kiver, Verena
    Solomayer, Erich-Franz
    Neeb, Caroline
    Blohmer, Jens-Uwe
    Abramian, Alina V.
    Maass, Nicolai
    Schuetz, Florian
    Kolberg-Liedtke, Cornelia
    Mueller, Carolin
    Rambow, Anna-Christina
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, 311 (02) : 423 - 427
  • [6] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
  • [7] Evaluate the impact of HER2 status on the response to CDK4/6 inhibitors in advanced breast cancer
    Goncalves, M. Veloso
    Teixeira, C.
    Valente, A. C.
    Reis, J.
    Teixeira, N.
    Sousa, I.
    Almeida, D.
    Augusto, I.
    Barbosa, M.
    Meireles, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 55 - 55
  • [8] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Hu, Qing-Lin
    Xu, Wei-Yun
    FRONTIERS IN ONCOLOGY, 2024, 14
12345